Moderna's medical officer on how it felt to learn vaccine is 94.5% effective

London (CNN Business)US stocks were poised to hit new record highs on Monday after Moderna said that its experimental Covid-19 vaccine is highly effective, heralding another breakthrough in the fight against coronavirus that could eventually help the world’s biggest economies recover from deep recessions.

Moderna (MRNA) said in a statement that the first interim analysis of Phase 3 trial results showed its vaccine candidate was 94.5% effective against the coronavirus. Last week, Pfizer (PFE) said that a vaccine it developed with German drugmaker BioNTech was more than 90% effective against Covid-19.
There are dozens more potential vaccines in development, and the promising test results from Moderna and Pfizer suggest that vaccines may be an effective way to fight the coronavirus. Both vaccines require two doses to be administered.

    Moderna's coronavirus vaccine is 94.5% effective, according to company data
    US stock futures rose after Moderna announced the results. Dow futures added 1.7%, or 486 points. S&P 500 futures increased 1.1% and Nasdaq futures advanced 0.1%. Shares in Moderna were up 11% in premarket trading.
    Investor optimism over vaccines helped propel the S&P 500 (DVS) to a record close on Friday. The Nasdaq (NDX) is 1.9% away from its record, while the Dow (INDU) is 0.2% short of its all-time high.

    Neil Shearing, group chief economist at Capital Economics, wrote in a research note on Monday before the Moderna results were announced that vaccine breakthroughs show “there is finally light at the end of the tunnel.”
    “Forget the fact President Trump has refused to concede defeat in the US election, or that Europe and the US remain gripped by new waves of the virus, or that another key Brexit deadline has passed and a ‘no deal’ exit is edging closer. Markets are focused on the increasing likelihood of a vaccine breakthrough,” he wrote.
    Don't expect a coronavirus vaccine before December, experts caution
    Yet there are reasons for investors to temper their enthusiasm. It will take months for the vaccines to be distributed, and the number of coronavirus cases in the United States is surging. Big economies in Europe such as France, Germany, and the United Kingdom have been locked down for a second time.

      Moderna said Monday that it expects to have roughly 20 million doses of its vaccine ready to ship in the United States by the end of this year. The company is on track to manufacture 500 million to 1 billion doses globally in 2021, it added.
      Pfizer told CNN last week that it expects to have 50 million vaccine doses globally this year, and 1.3 billion in 2021.
      Source: Read Full Article